Zimmer, ISTO start Phase III study of DeNovo tissue graft

Partners Zimmer Holdings ($ZMH) and orthobiologics company ISTO Technologies are working together on a Phase III clinical study to evaluate the DeNovo ET engineered tissue graft to help repair cartilage defects in the knee. The study will include 225 patients at up to 25 U.S. centers. The program is designed to demonstrate superiority of the graft over the current standard of care for articular cartilage defects. Release

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.